|
|
41
|
|
|
B6211
|
|
|
GLYXAMBI 25MG|5MG TAB (BOE) EMPAGL (C)
|
|
|
EMPAGLIFLOZIN|LINAGLIPTIN
|
|
|
GLYXAMBI
|
|
|
30'S
|
|
|
C
|
|
|
118.79
|
|
|
3.9597
|
|
|
25MG|5MG
|
|
|
TAB
|
|
|
0
|
|
|
BOX
|
|
|
BOE
|
|
|
BOEHRINGER INGELHEIM
|
|
|
STO
|
|
|
BRYDEN STOKES LTD
|
|
|
|
|
|
Anti-Diabetic
|
|
|
2024-04-01
|
|
|
2026-03-31
|
|
|
|
|
|
|
|
|
|
|
|
0
|
|
|
|
|
|
682005
|
|
|
DIPEPTIDYL PEPTIDASE INHIBITORS
|
|
|
|
|
|
ORAL
|
|
|
0
|
|
|
DIPEPTIDYL PEPTIDASE INHIBITORS
|
|
|
2024-01-02
|